Marshall Wace LLP Reduces Stock Position in Bioventus Inc. (NYSE:BVS)

Marshall Wace LLP reduced its position in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 80.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,423 shares of the company's stock after selling 307,404 shares during the quarter. Marshall Wace LLP owned about 0.09% of Bioventus worth $771,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in BVS. Vanguard Group Inc. grew its stake in Bioventus by 18.7% in the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock valued at $25,852,000 after purchasing an additional 388,174 shares during the last quarter. American Century Companies Inc. boosted its position in Bioventus by 38.7% during the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company's stock worth $9,289,000 after purchasing an additional 246,645 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after purchasing an additional 176,442 shares during the period. Sheets Smith Investment Management purchased a new position in shares of Bioventus in the fourth quarter valued at approximately $1,499,000. Finally, Kennedy Capital Management LLC boosted its stake in Bioventus by 80.2% during the 4th quarter. Kennedy Capital Management LLC now owns 213,984 shares of the company's stock worth $2,247,000 after purchasing an additional 95,266 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Performance

Shares of BVS traded down $0.31 during midday trading on Monday, reaching $7.03. 762,345 shares of the stock were exchanged, compared to its average volume of 457,509. The company has a market capitalization of $576.07 million, a price-to-earnings ratio of -11.52 and a beta of 0.95. Bioventus Inc. has a twelve month low of $3.95 and a twelve month high of $14.38. The business's 50-day moving average price is $8.74 and its 200 day moving average price is $10.27. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99.

Insider Buying and Selling

In other news, CFO Mark Leonard Singleton sold 3,875 shares of Bioventus stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the sale, the chief financial officer now owns 141,088 shares of the company's stock, valued at $1,068,036.16. The trade was a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Anthony D'adamio sold 4,380 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the transaction, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,208 shares of company stock valued at $226,138 over the last quarter. 32.90% of the stock is currently owned by insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.